The ELEVATE Study shows that atogepant effectively prevents episodic migraine.

Published Date: 24 Apr 2023

Atogepant (Qulipta) performed better than a placebo in the ELEVATE study for preventing episodic migraine in patients who were resistant to other treatments.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Celebrity Cancers Stoking Fear? Cisplatin Shortage Ends; Setback for Anti-TIGIT

2.

Promising OS at 5 Years With Chemo-Free Combo in Urothelial Cancer

3.

Resection for Early Liver Cancer Tied to Improved Survival.

4.

Study: Pre-operative THP leads to pCR in 64% of early-stage HER2+ ER- breast cancer patients

5.

Prior authorizations draining time, energy from many cancer patients


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot